The EU-AIMS Longitudinal European Autism Project (LEAP): design and methodologies to identify and validate stratification biomarkers for autism spectrum disorders.

Eva Loth 1 Tony Charman 1 Luke Mason 2 Julian Tillmann 1 Emily J.H Jones 2 Carolin Wooldridge 1 Jumana Ahmad 1 Bonnie Auyeung 3, 4 Claudia Brogna 5 Sara Ambrosino 6 Tobias Banaschewski 7, 8 Simon Baron-Cohen 4 Sarah Baumeister 8, 7 Christian Beckmann 9 Michael Brammer 1 Daniel Brandeis 10, 8, 7 Sven Bölte 11 Thomas Bourgeron 12 Carsten Bours 9 Yvette De Bruijn 9 Bhismadev Chakrabarti 13, 4 Daisy Crawley 1 Ineke Cornelissen 9 Flavio Dell' Acqua 1 Guillaume Dumas 12 Sarah Durston 6 Christine Ecker 14, 1 Jessica Faulkner 1 Vincent Frouin 15 Pilar Garces 16 David Goyard 15 Hannah Hayward 1 Lindsay M Ham 17 Joerg Hipp 16 Rosemary J Holt 4 Mark H Johnson 2 Johan Isaksson 18, 10 Prantik Kundu 19 Meng-Chuan Lai 20, 4 Xavier Liogier D’ardhuy 16 Michael V. Lombardo 21, 4 David J Lythgoe 1 René Mandl 6 Andreas Meyer-Lindenberg 8, 7 Carolin Moessnang 8, 7 Nico Mueller 8, 7 Laurence O’dwyer 9 Marianne Oldehinkel 9 Bob Oranje 6 Gahan Pandina 22 Antonio M Persico 23, 5 Amber N V Ruigrok 4 Barbara Ruggeri 1 Jessica Sabet 1 Roberto Sacco 5 Antonia San José Cáceres 1 Emily Simonoff 1 Roberto Toro 12 Heike Tost 8, 7 Jack Waldman 4 Will Williams 1 Marcel P Zwiers 9 Will Spooren 16 Declan G M Murphy 1 Jan K Buitelaar 9
Résumé : The tremendous clinical and aetiological diversity among individuals with autism spectrum disorder (ASD) has been a major obstacle to the development of new treatments, as many may only be effective in particular subgroups. Precision medicine approaches aim to overcome this challenge by combining pathophysiologically based treatments with stratification biomarkers that predict which treatment may be most beneficial for particular individuals. However, so far, we have no single validated stratification biomarker for ASD. This may be due to the fact that most research studies primarily have focused on the identification of mean case-control differences, rather than within-group variability, and included small samples that were underpowered for stratification approaches. The EU-AIMS Longitudinal European Autism Project (LEAP) is to date the largest multi-centre, multi-disciplinary observational study worldwide that aims to identify and validate stratification biomarkers for ASD.
Liste complète des métadonnées

Littérature citée [122 références]  Voir  Masquer  Télécharger

https://hal-pasteur.archives-ouvertes.fr/pasteur-01557947
Contributeur : Guillaume Dumas <>
Soumis le : jeudi 6 juillet 2017 - 16:49:58
Dernière modification le : jeudi 29 mars 2018 - 10:32:02

Fichier

Loth_2017_Mol_Autism.pdf
Publication financée par une institution

Licence


Distributed under a Creative Commons Paternité 4.0 International License

Identifiants

Citation

Eva Loth, Tony Charman, Luke Mason, Julian Tillmann, Emily J.H Jones, et al.. The EU-AIMS Longitudinal European Autism Project (LEAP): design and methodologies to identify and validate stratification biomarkers for autism spectrum disorders.. Molecular Autism, BioMed Central, 2017, 8 (1), pp.24. 〈10.1186/s13229-017-0146-8〉. 〈pasteur-01557947〉

Partager

Métriques

Consultations de la notice

334

Téléchargements de fichiers

120